About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

15.91 +0.26 (+1.67%)
Streaming Delayed Price Updated: 10:43 AM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway 
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces $500 million Private Placement Equity Financing
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement 
From Denali Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.